Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010)

Misra, Ramnath; Danda, Debashish; Rajappa, Sivakumar; Ghosh, Alakendu; Gupta, Rajiva; Mahendranath, Kurugodu M.; Jeyaseelan, Lakshmanan; Lawrence, Able; Bacon, P. A.

doi:10.1093/rheumatology/ket128

Cited by 274 publications

(222 citation statements)

References 23 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…This has been validated in adult TA. 64 TADS was also derived from DEI.Tak to capture the extent of damage caused by the disease. It consists of 42 items in seven systems, with a strong emphasis on cardiovascular system items and takes into account features present for at least 3 months.…”

Section: Assessing Disease Activitymentioning

confidence: 99%

Childhood‐onset Takayasu arteritis: an update

et al. 2015

Self Cite

View full text Add to dashboard Cite

Childhood-onset Takayasu arteritis (c-TA) is a distinct subset affecting a wide age group, ranging from young infants to adolescents and it differs from adult TA in many aspects. There is scarcity of data on c-TA worldwide. The disease is classified using the European League Against Rheumatism/Pediatric Rheumatology International Trials Organization/Pediatric Rheumatology European Society criteria. The non-specific nature of presenting complaints and lack of appropriate biomarkers delay the early diagnosis of this illness and many children present with complications, which become irreversible once they set in. One of the largest cohorts of 40 children with c-TA from our center reports hypertension as the commonest presenting feature. Systemic symptoms like headache, fever and weight loss are also described. Assessment of disease in c-TA is done by correlating clinical features with raised inflammatory markers. Advanced imaging plays an important role in diagnosis. In c-TA, the role of magnetic resonance angiography is advocated, taking into consideration the enormous amount of radiation exposure with other modalities. Complications of c-TA include cardiovascular, pulmonary, neurological and those arising secondary to long-term steroid and immunosuppression therapy.

show abstract

Section: Assessing Disease Activitymentioning

confidence: 99%

Childhood‐onset Takayasu arteritis: an update

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…This includes dose reduction of immunosuppressants, which should be used in combination with tocilizumab, as in the current study. Further, the accuracy of disease activity indices, such as the US National Institutes of Health (NIH) criteria and Indian Takayasu Clinical Activity Score (ITAS) 2010 4,16 , which incorporate ESR and/or CRP, may be compromised, a fact recognized by the authors 15 .…”

Section: Rheumatologymentioning

confidence: 99%

Interleukin 6 Targeting in Refractory Takayasu Arteritis: Serial Noninvasive Imaging is Mandatory to Monitor Efficacy

Youngstein

Mason

2013

J Rheumatol

View full text Add to dashboard Cite

“…Его модификация, ITAS-A, включает, помимо клинических данных, также СОЭ или СРБ. В нашем исследовании мы использовали ITAS2010, но не ITAS-A, поскольку значения последнего, как показано в исследованиях, могут оставаться повы-шенными в течение длительного времени (до года) после получения ответа на терапию, что может вводить в заблу-ждение [20]. Таким образом, ITAS2010 характеризует именно клиническую активность заболевания.…”

Section: Discussionunclassified

“…), не имеющие альтернативного объяснения; повышение СОЭ в отсутствие инфекции и других возможных причин; признаки сосудистой недостаточности («хромота» конеч-ностей, нижней челюсти, уменьшение или отсутствие со-судистой пульсации, сосудистый шум, боли в области ар-терий -каротодинии, асимметрия артериального давле-ния на верхних/нижних конечностях), признаки прогрес-сирования по данным визуализирующих методов [1]. Так-же с целью оценки активности болезни использовался ин-декс Indian Takayasu Clinical Activity Score (ITAS2010), в который включены 6 блоков по системам органов [20]. Для анализа полученных данных применяли методы опи-сательной статистики.…”

Section: материал и методыunclassified

Certolizumab Pegol in the Treatment of Takayasu Arteritis: The First Experience and Prospects

Novikov¹,

Smitienko²,

Соколова³

et al. 2018

rsp

View full text Add to dashboard Cite

Certolizumab pegol (CZP) is the only pegylated biological agent (BA) that does not contain an Fc fragment, which minimizes its transplacental transfer. Takayasu arteritis mostly occurs in reproductive-aged women.Objective: to evaluate the efficacy and safety of CZP used to treat standard immunosuppressive therapy-resistant Takayasu arteritis.Subjects and methods. The retrospective study enrolled 6 female patients aged 18 to 35 years with Takayasu arteritis who received CZP. The median disease duration before BA usage was 66 months (24 to 204 months). The median duration of immunosuppressive therapy prior to CZP treatment was 92 months (14 to 132 months). All the female patients had taken glucocorticoids and methotrexate before and during CZP therapy. Only four patients had received two to five immunosuppressive drugs at different times prior to BA administration. Three patients had previously used other BAs. The disease activity was determined by the National Institute of Health (NIH) criteria. The Indian Takayasu Clinical Activity Score (ITAS2010) was used. The disease activity was recorded in all the patients prior to CZP therapy.Results and discussion. The median duration of CZP treatment was 17 months (6 to 24 months). The median erythrocyte sedimentation rate after CZP usage decreased from 22.5 to 10.5 mm/h; the median C-reactive protein level dropped from 7.8 to 0.39 mg/dl (p<0.05), the median daily dose of prednisolone was reduced from 20 to 8.75 mg (p<0.05). All the patients achieved complete remission an average of 4 months after starting CZP therapy. Three patients were still in remission after 12–24 months. One relapse of the disease was recorded following 24 months. ITAS2010 reduced from 1–4 to 0 in five patients and to 2 in one patient with recurrence. There was a good tolerance in five female patients. The adverse events were herpes labialis in two cases, community-acquired pneumonia in one case, and postoperative abscess in one case too.Conclusion. CZP in Takayasu arteritis was shown to be an effective drug for remission induction and maintenance. The presented results of the first experience in treating this disease with CZP are indicative of its promising further investigation as a steroid-sparing drug in patients with refractory vasculitis. One of the important advantages of CZP is its supposed high safety throughout pregnancy.

show abstract

Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010)

Abstract: The ITAS2010, validated in over 300 TA patients and sensitive to change, is a useful measure of clinical disease activity for patient monitoring. Higher ITAS-A scores suggest poor control of active disease by current therapy.

Cited by 274 publications

References 23 publications

Childhood‐onset Takayasu arteritis: an update

Childhood‐onset Takayasu arteritis: an update

Interleukin 6 Targeting in Refractory Takayasu Arteritis: Serial Noninvasive Imaging is Mandatory to Monitor Efficacy

Certolizumab Pegol in the Treatment of Takayasu Arteritis: The First Experience and Prospects

Contact Info

Product

Resources

About